Warrant to purchase shares of Common Stock - Johannes W.G. Vieweg, M.D.



 Exhibit 10.3 
 NEITHER THIS WARRANT NOR THE SHARES OF STOCK ISSUABLE UPON EXERCISE HEREOF HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. NO SALE, TRANSFER OR OTHER DISPOSITION OF THIS WARRANT OR
SAID SHARES MAY BE EFFECTED WITHOUT (i) AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO, (ii) AN OPINION OF COUNSEL FOR THE HOLDER, REASONABLY SATISFACTORY TO THE COMPANY, THAT SUCH REGISTRATION IS NOT REQUIRED OR (iii) RECEIPT OF
A NO-ACTION LETTER FROM THE SECURITIES AND EXCHANGE COMMISSION TO THE EFFECT THAT REGISTRATION UNDER THE ACT IS NOT REQUIRED. 
 Shares
Issuable Upon Exercise: Up to 480,000 
 Warrant No. W-76 
 WARRANT TO 
 PURCHASE SHARES OF COMMON STOCK 

Expires February 5, 2013 
 THIS CERTIFIES THAT, for value received, Johannes W.G. Vieweg, M.D. (hereinafter referred to as “Initial Holder,” and, along with any other registered holder of this Warrant, as
“Holder”) is entitled to subscribe for and purchase up to Four Hundred Eighty Thousand (480,000) of the fully paid and nonassessable shares of the Common Stock, par value $0.001 per share (the “Common Stock”), of Argos
Therapeutics, Inc., a Delaware corporation (the “Company”), at a price of $0.18 per share. The shares issuable upon exercise of this Warrant, as adjusted pursuant to the provisions hereof, are referred to as the “Shares”. The
purchase price of each Share and such other price as shall result, from time to time, from adjustments specified herein is herein referred to as the “Warrant Price”, subject to the provisions and upon the terms and condition hereinafter
set forth. This Warrant is being issued pursuant to a written compensatory contract under Rule 701 promulgated under the Securities Act of 1933, as amended (“Rule 701”), and it is the intent of the Company and the Initial Holder that this
Warrant is issued under and in compliance with this Rule 701. This Warrant is issued as a replacement of Warrant W-73 for the purchase of up to 800,000 shares of common stock, which warrant W-73 is null and void. 

1. Term. (a) This Warrant shall be exercisable, subject to the vesting schedule set forth below, until February 5, 2013:

 (i) On and after March 31, 2005, this Warrant may be exercised to purchase up to 320,000 Shares; and

 (ii) With respect to the remaining 160,000 Shares, upon the first to occur of completion of a Phase I clinical
trial sponsored by the Company (as defined in the Consulting Agreement, dated March 31, 2005, by and between the Initial Holder and the Company (the “Consulting Agreement”)) or September 30, 2005. 







 Upon the completion of clause (ii) of this Section 1, this Warrant may be exercised to purchase up
to 100% of the Shares, provided, however, that all Shares shall be immediately exercisable in the event that (A) the Initial Holder terminates his consultancy pursuant to Section 6.2(a) of the Consulting Agreement or
(B) the Company terminates the Initial Holder’s consultancy pursuant to Section 6.2(c) of the Consulting Agreement. In the event that the Initial Holder terminates his consultancy pursuant to Section 6.2(c) of the Consulting
Agreement, all warrants that have not been exercised at the time of such termination shall terminate and no longer be exercisable. 
 (b) Notwithstanding the foregoing, in the event of a merger, consolidation, corporate reorganization, or any transaction in which all or substantially all of the assets or stock of the Company are sold,
leased, transferred or otherwise disposed of (other than a mere reincorporation transaction or one in which the holders of capital stock of the Company immediately prior to such merger or consolidation continue to hold at least a majority of the
voting power of the surviving corporation) (a “Transfer of Control”), any unexercisable portion of this warrant that will become exercisable after the Transfer of Control shall become immediately exercisable as of a date prior to the
Transfer of Control, which date shall be determined by the Board of Directors of the Company (the “Board”). The exercise of any Shares that was permissible solely by reason of this Section l(b) shall be conditioned upon the consummation of
the Transfer of Control. The Board may further elect, in its sole discretion, to provide that any Shares which are not exercised as of the date of the Transfer of Control shall terminate effective as of the date of the Transfer of Control.

 2. Method of Exercise. The purchase right represented by this Warrant may be exercised by Holder hereof, in whole or
in part, by either, at the election of Holder hereof, the surrender of this Warrant (with the notice of exercise form attached hereto as Exhibit A duly executed) at the principal office of the Company, and by the payment in full to the
Company, by check, of an amount equal to the then applicable Warrant Price per share multiplied by the number of Shares then being purchased. The person or persons in whose name(s) any certificate(s) representing shares of Common Stock shall be
issuable upon exercise of this Warrant shall be deemed to have become the holder(s) of record of, and shall be treated for all purposes as the record Holder(s) of, the shares represented thereby (and such shares shall be deemed to have been issued)
immediately prior to the close of business on the date or dates upon which this Warrant is exercised. In the event of any exercise of the rights represented by this Warrant, certificates for the shares of stock so purchased shall be delivered to the
Holder hereof as soon as possible and in any event within thirty (30) days of receipt of such notice and, unless this Warrant has been fully exercised or expired, a new Warrant representing the portion of the Shares, if any, with respect to
which this Warrant shall not then have been exercised shall also be issued to the Holder hereof as soon as possible and in any event within such thirty-day period, The exercise of this Warrant is expressly conditioned upon the person in whose name
any shares issuable upon the exercise hereof are to be issued becoming party to, and agreeing to be bound by the terms of, the Company’s First Amended and Restated Stockholders’ Agreement (as such agreement may be amended and/or restated
from time to time). 

  
 2 








 3. Stock Fully Paid; Reservation of Shares. All Shares that may be issued upon the
exercise of the rights represented by this Warrant will, upon issuance, be fully paid and nonassessable, and free from all taxes, liens and charges with respect to the issue thereof. During the period within which the rights represented by the
Warrant may be exercised, the Company will at all times have authorized and reserved for the purpose of issuance upon exercise of the purchase rights evidenced by this Warrant, a sufficient number of shares of its stock to provide for the exercise
of the right represented by this Warrant. 
 4. Adjustment of Warrant Price and Number of Shares. The number and kind of
securities purchasable upon the exercise of the Warrant and the Warrant Price shall be subject to adjustment from time to time upon the occurrence of certain events, as follows: 

(a) Reclassification or Merger. In case of any reclassification, change or conversion of securities of the class issuable upon
exercise of this Warrant (other than a change in par value, or from par value to no par value, or from no par value to par value, or as a result of a subdivision or combination), or in case of any merger of the Company with or into another
corporation (other than a merger with another corporation in which the Company is a continuing corporation and which does not result in any reclassification or change of outstanding securities issuable upon exercise of this Warrant), or in case of
any sale of all or substantially all of the assets of the Company, the Company, or such successor or purchasing corporation, as the case may be, shall execute a new Warrant providing that the holder of this Warrant shall have the right to exercise
such new Warrant and upon such exercise to receive, in lieu of each share of stock theretofore issuable upon exercise of this Warrant, the kind and amount of shares of stock, other securities, money and property receivable upon such
reclassification, change or merger by a holder of one share of stock issuable upon the exercise hereof. Such new Warrant shall provide for adjustments that shall be as nearly equivalent as may be practicable to the adjustments provided for in this
Paragraph 4. The provisions of this subparagraph (a) shall similarly apply to successive reclassifications, changes, mergers and transfers. In lieu of the foregoing, in the event of (i) any consolidation or merger of the Company with or
into any other corporation, or (ii) any sale of all or substantially all of the assets of the Company, in either case in which the Company shall not be the continuing surviving entity and which results in a reclassification or change of
outstanding securities issuable upon exercise of this Warrant, then the Company shall have the option to purchase this Warrant on the closing date of such event for cash or freely-tradable, unrestricted securities in an amount per share equal to the
excess (if any) of the Market Value (as defined herein) of the Shares over the Warrant Price. The “Market Value” of each Share shall be defined as the amount determined by dividing the total consideration to be received by the Company or
its stockholders in connection with such event by the number of shares of common stock then outstanding, assuming that all convertible securities of the Company have been converted into common stock. Any securities to be delivered to the Company or
its security holders shall be valued as follows: Fair market value of the securities shall mean the average of the closing bid and asked prices of the securities quoted in the Over-The-Counter Market Summary or the closing price quoted on any
exchange on which the securities are listed, whichever is applicable, as published in the Eastern Edition of The Wall Street Journal for the ten (10) trading days prior to the date of determination of fair market value or if not so
registered, then the fair market value as mutually agreed to by the Holder and the Board (or if they are unable to agree, as determined by a mutually agreed independent third party appraisal, whose fees shall be paid by the Company). 

  
 3 








 (b) Subdivisions or Combination of Shares. If the Company at any time while this
Warrant remains outstanding and unexpired shall subdivide or combine its stock, the Warrant Price and the number of Shares issuable upon exercise hereof shall be proportionately adjusted. 

(c) Stock Dividends. If the Company at any time while this Warrant is outstanding and unexpired shall pay a dividend payable in
shares of stock (except any distribution specifically provided for in the foregoing subparagraphs (a) and (b)), then the Warrant Price shall be adjusted, from and after the date of determination of stockholders entitled to receive such dividend
or distribution, to that price determined by multiplying the Warrant Price in effect immediately prior to such date of determination by a fraction (a) the numerator of which shall be the total number of shares of common stock outstanding
immediately prior to such dividend or distribution, assuming that all convertible securities of the Company have been converted into common stock and (b) the denominator of which shall be the total number of shares of common stock outstanding
immediately after such dividend or distribution, assuming that all convertible securities of the Company have been converted into common stock, and the number of Shares subject to this Warrant shall be proportionately adjusted. 

(d) No Impairment. The Company will not, by amendment of its Certificate of Incorporation or through any reorganization,
recapitalization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms to be observed or performed hereunder by
the Company, but will at all times in good faith assist in the carrying out of all the provisions of this Paragraph 4 and in the taking of all such action as may be necessary or appropriate in order to protect the rights of the holder of this
Warrant against impairment. 
 (e) Notices of Record Date. In the event of any taking by the Company of a record of its
stockholders for the purpose of determining stockholders who are entitled to receive payment of any dividend (other than a cash dividend) or other distribution, any right to subscribe for, purchase or otherwise acquire any share of any class or any
other securities or property, or to receive any other right, or for the purpose of determining stockholders who are entitled to vote in connection with any proposed merger or consolidation of the Company with or into any other corporation, or any
proposed sale, lease or conveyance of all or substantially all of the assets of the Company, or any proposed liquidation, dissolution or winding up of the Company, the Company shall mail to the holder of the Warrant, at least twenty (20) days
prior to the date specified therein, a notice specifying the date on which any such record is to be taken for the purpose of such dividend, distribution or right, and the amount and character of such dividend, distribution or right. 

5. Notice of Adjustments. Whenever the Warrant Price shall be adjusted pursuant to the provisions hereof, the Company shall within
thirty (30) days of such adjustment deliver a certificate signed by its chief financial officer to the registered holder(s) hereof setting forth, in reasonable detail, the event requiring the adjustment, the amount of the adjustment, the method
by which such adjustment was calculated, and the Warrant Price after giving effect to such adjustment. 

  
 4 








 6. Fractional Share. No fractional shares of stock will be issued in connection with
any exercise hereunder, but in lieu of such fractional shares the Company shall make a cash payment therefor upon the basis of the then fair market value of the stock to be issued upon the exercise hereof. 

7. Requirements for Transfer. 
 (a) The Holder of this Warrant, by acceptance hereof, agrees that this Warrant and the Shares to be issued upon exercise hereof are being acquired for investment and that such holder will not offer, sell
or otherwise dispose of this Warrant or any Shares to be issued upon exercise hereof unless either (i) they first shall have been registered under the Securities Act of 1933, as amended (the “Act”), or (ii) the Company first
shall have been furnished with an opinion of legal counsel, reasonably satisfactory to the Company, to the effect that such sale or transfer is exempt from the registration requirements of the Act. 

(b) [omitted] 

(c) This Warrant and all Shares issued upon exercise of this Warrant (unless registered under the Act) shall be stamped or imprinted with
a legend in substantially the following form: 
 “The securities represented by this certificate have not been registered
under the Securities Act of 1933, as amended, and may not be offered, sold or otherwise transferred, pledged or hypothecated unless and until such securities are registered under such Act or an opinion of counsel satisfactory to the Company is
obtained to the effect that such registration is not required.” 
 The foregoing legend may be removed from the certificates representing
any Shares issued upon exercise hereof, at the request of the holder thereof, at such time as they become eligible for resale pursuant to Rule 144(k) under the Act. All Shares issued upon exercise of this Warrant (unless registered under the Act)
shall also be imprinted with any legend required by the Company’s First Amended and Restated Stockholders’ Agreement (as such agreement may be amended and/or restated from time to time). 

8. Rights as Stockholders. No holder of the Warrant, as such, shall be entitled to vote or receive dividends or be deemed the
holder of Common Stock or any other securities of the Company which may at any time be issuable on the exercise thereof for any purpose, nor shall anything contained herein be construed to confer upon the holder of this Warrant, as such, any of the
rights of a stockholder of the Company or any right to vote for the election of directors or upon any matter submitted to stockholders at any meeting thereof, or to receive notice of meetings, or to receive dividends or subscription rights or
otherwise until this Warrant shall have been exercised and the Shares purchasable upon the exercise hereof shall have become deliverable, as provided herein. 

  
 5 








 9. Modification and Waiver. This Warrant and any provisions hereof may be changed,
waived, discharged or terminated only by an instrument in writing signed by the party against which enforcement of the same is sought. 
 10. Notices. Any notice, request or other document required or permitted to be given or delivered to the holder hereof or the Company shall be personally delivered, or shall be sent by certified or
registered mail, postage prepaid, to each such holder at its address as shown on the books of the Company or to the Company at the address indicated therefore on the signature page of this Warrant. 

11. Binding Effect on Successors. This Warrant shall be binding upon any corporation succeeding the Company by merger,
consolidation or acquisition of all or substantially all of the Company’s assets, and all of the obligations of the Company relating to the Shares issuable upon the exercise of this Warrant shall survive the exercise and termination of this
Warrant and all of the covenants and agreements of the Company shall inure to the benefit of the successors and assigns of the holder hereof. 
 12. Lost Warrants or Stock Certificates. The Company covenants to the holder hereof that upon receipt of evidence reasonably satisfactory to the Company of the loss, theft, destruction, or
mutilation of this Warrant or any stock certificate and, in the case of any such loss, theft or destruction, upon receipt of an indemnity agreement reasonably satisfactory to the Company, or in the case of any such mutilation upon surrender and
cancellation of such Warrant or stock certificate, the Company will make and deliver a new Warrant or stock certificate, of like tenor, in lieu of the lost, stolen, destroyed or mutilated Warrant or stock certificate. 

13. Descriptive Headings. The descriptive headings of the several paragraphs of this Warrant are inserted for convenience only and
do not constitute apart of this Warrant. 
 14. Exchange of Warrants. Upon the surrender by Holder of any Warrant or
Warrants, properly endorsed, to the Company at the principal office of the Company, the Company will, subject to the provisions of Paragraph 7 hereof, issue and deliver to or upon the order of such Holder, at the Company’s expense, a new
Warrant or Warrants of like tenor, in the name of such Holder or as such Holder (upon payment by such Holder of any applicable transfer taxes) may direct, calling in the aggregate on the face or faces thereof for the number of shares of stock called
for on the face or faces of the Warrant or Warrants so surrendered. 
 15. Transfers, etc. 

(a) The Company will maintain a register containing the names and addresses of the Holders of this Warrant. Any Holder may change its or
his address as shown on the warrant register by written notice to the Company requesting such change. 
 (b) Subject to the
provisions of Paragraph 7 hereof, this Warrant and all rights hereunder are transferable, in whole or in part, upon surrender of this Warrant with a properly executed assignment (in the form of Exhibit B attached hereto) at the principal
office of the Company. 

  
 6 








 (c) Until any transfer of the Warrant is made in the warrant register, the Company may treat
the registered Holder of this Warrant as the absolute owner hereof for all purposes; provided, however, that if and when this Warrant is properly assigned in blank, the Company may (but shall not be obligated to) treat the bearer
hereof as the absolute owner hereof for all purposes, notwithstanding any notice to the contrary. 
 16. Governing Law.
THIS WARRANT SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH, AND THE RIGHTS OF THE PARTIES SHALL BE GOVERNED BY, THE LAWS OF THE STATE OF DELAWARE. 

 

			
	 Argos Therapeutics, Inc.
 4233 Technology Drive
 Durham, NC 27704

		
	By:	 	 





		 	 Clint G. Dederick, Jr.

President and Chief Executive Officer



 Date: March 31, 2005 

  
 7 








 EXHIBIT A 

Notice of Exercise 
 To:

 1. The undersigned hereby elects to purchase              shares
of the Common Stock of Argos Therapeutics, Inc. pursuant to the terms of the attached Warrant (Warrant No. W-76), and tenders herewith payment of the purchase price of such shares in full. 

2. Please issue a certificate or certificates representing said shares in the name of the undersigned or in such other name or names as
are specified below: 
  

									
	 Name
	 	  	 	  	 	 Address
	 	  
			
	  
	 		 	  

			
	  
	 		 	  

			
	  
	 		 	  

			
		 		 	  

		 		 	(Signature)	 	
					
	  
	 		 		 		 	
	 (Date)
	 		 		 		 	


  
 8 








 EXHIBIT B 

Assignment Form 

FOR VALUE RECEIVED,
                     hereby sells, assigns and transfers all of the rights of the undersigned under the attached Warrant (Warrant No. W-76) with
respect to the number of shares of stock covered thereby set forth below, unto: 
  

					
	Name of Assignee	    	Address	    	No. of Shares
			
	  
	    	  
	    	  

			
	  
	    	  
	    	  

			
	  
	    	  
	    	  


  

					
			
	  
	 		 	  

	(Date)	 		 	(Signature)
			
	  
	 		 	  

	(Date)	 		 	(Signature)


  
 9